287 related articles for article (PubMed ID: 8932544)
21. Liposomal doxorubicin in the treatment of advanced AIDS-related Kaposi sarcoma.
Bogner JR; Kronawitter U; Rolinski B; Truebenbach K; Goebel FD
J Acquir Immune Defic Syndr (1988); 1994 May; 7(5):463-8. PubMed ID: 8158540
[TBL] [Abstract][Full Text] [Related]
22. Accumulation of liposomal lipid and encapsulated doxorubicin in murine Lewis lung carcinoma: the lack of beneficial effects by coating liposomes with poly(ethylene glycol).
Parr MJ; Masin D; Cullis PR; Bally MB
J Pharmacol Exp Ther; 1997 Mar; 280(3):1319-27. PubMed ID: 9067319
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness analysis comparing liposomal anthracyclines in the treatment of AIDS-related Kaposi's sarcoma.
Bennett CL; Golub RM; Stinson TJ; Aboulafia DM; von Roenn J; Bogner J; Goebel FD; Stewart S
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Aug; 18(5):460-5. PubMed ID: 9715842
[TBL] [Abstract][Full Text] [Related]
24. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy.
Gabizon AA
Cancer Invest; 2001; 19(4):424-36. PubMed ID: 11405181
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness analysis of pegylated-liposomal doxorubicin and liposomal daunorubicin treatments in patients with Kaposi's sarcoma.
Hjortsberg C; Persson U; Lidbrink E; Bennett C
Acta Oncol; 1999; 38(8):1063-7. PubMed ID: 10665764
[TBL] [Abstract][Full Text] [Related]
26. Liposomal doxorubicin (Doxil): an effective new treatment for Kaposi's sarcoma in AIDS.
James ND; Coker RJ; Tomlinson D; Harris JR; Gompels M; Pinching AJ; Stewart JS
Clin Oncol (R Coll Radiol); 1994; 6(5):294-6. PubMed ID: 7530036
[TBL] [Abstract][Full Text] [Related]
27. Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients.
La-Beck NM; Zamboni BA; Gabizon A; Schmeeda H; Amantea M; Gehrig PA; Zamboni WC
Cancer Chemother Pharmacol; 2012 Jan; 69(1):43-50. PubMed ID: 21590446
[TBL] [Abstract][Full Text] [Related]
28. Treatment of Kaposi's sarcoma with liposomal doxorubicin.
Bergin C; O'Leary A; McCreary C; Sabra K; Mulcahy F
Am J Health Syst Pharm; 1995 Sep; 52(18):2001-4. PubMed ID: 8528867
[TBL] [Abstract][Full Text] [Related]
29. Phase II trial of liposomal daunorubicin in the treatment of AIDS-related pulmonary Kaposi's sarcoma.
Tulpule A; Yung RC; Wernz J; Espina BM; Myers A; Scadden DT; Cabriales S; Ilaw M; Boswell W; Gill PS
J Clin Oncol; 1998 Oct; 16(10):3369-74. PubMed ID: 9779714
[TBL] [Abstract][Full Text] [Related]
30. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial?
Hong RL; Huang CJ; Tseng YL; Pang VF; Chen ST; Liu JJ; Chang FH
Clin Cancer Res; 1999 Nov; 5(11):3645-52. PubMed ID: 10589782
[TBL] [Abstract][Full Text] [Related]
31. Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity.
Hong RL; Tseng YL
Cancer; 2001 May; 91(9):1826-33. PubMed ID: 11335910
[TBL] [Abstract][Full Text] [Related]
32. Liposomal doxorubicin in the treatment of AIDS-associated Kaposi's sarcoma: clinical, histological and cell biological evaluation.
Stürzl M; Zietz C; Eisenburg B; Goebel FD; Gillitzer R; Hofschneider PH; Bogner JR
Res Virol; 1994; 145(3-4):261-9. PubMed ID: 7800953
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics and its relation to toxicity of pegylated-liposomal doxorubicin in Chinese patients with breast tumours.
Xu L; Wang W; Sheng YC; Zheng QS
J Clin Pharm Ther; 2010 Oct; 35(5):593-601. PubMed ID: 20831683
[TBL] [Abstract][Full Text] [Related]
34. KS treatment inches forward.
Vazquez E
Posit Aware; 1996; 7(5):9. PubMed ID: 11363790
[TBL] [Abstract][Full Text] [Related]
35. Liposomal-entrapped doxorubicin: an active agent in AIDS-related Kaposi's sarcoma.
Harrison M; Tomlinson D; Stewart S
J Clin Oncol; 1995 Apr; 13(4):914-20. PubMed ID: 7707119
[TBL] [Abstract][Full Text] [Related]
36. Liposomal pegylated doxorubicin versus low-dose recombinant interferon Alfa-2a in the treatment of advanced classic Kaposi's sarcoma; retrospective analysis of three German centers.
Kreuter A; Rasokat H; Klouche M; Esser S; Bader A; Gambichler T; Altmeyer P; Brockmeyer NH
Cancer Invest; 2005; 23(8):653-9. PubMed ID: 16377582
[TBL] [Abstract][Full Text] [Related]
37. Treatment of classic Kaposi's sarcoma with liposomal encapsulated doxorubicin.
Gottlieb JJ; Washenik K; Chachoua A; Friedman-Kien A
Lancet; 1997 Nov; 350(9088):1363-4. PubMed ID: 9365453
[No Abstract] [Full Text] [Related]
38. Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection.
Laverman P; Carstens MG; Boerman OC; Dams ET; Oyen WJ; van Rooijen N; Corstens FH; Storm G
J Pharmacol Exp Ther; 2001 Aug; 298(2):607-12. PubMed ID: 11454922
[TBL] [Abstract][Full Text] [Related]
39. Treatment of HIV-1-associated Kaposi's sarcoma with pegylated liposomal doxorubicin and HAART simultaneously induces effective tumor remission and CD4+ T cell recovery.
Lichterfeld M; Qurishi N; Hoffmann C; Hochdorfer B; Brockmeyer NH; Arasteh K; Mauss S; Rockstroh JK;
Infection; 2005 Jun; 33(3):140-7. PubMed ID: 15940415
[TBL] [Abstract][Full Text] [Related]
40. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group.
Stewart S; Jablonowski H; Goebel FD; Arasteh K; Spittle M; Rios A; Aboulafia D; Galleshaw J; Dezube BJ
J Clin Oncol; 1998 Feb; 16(2):683-91. PubMed ID: 9469358
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
